课题基金 / 基金详情

Study on plasma HDL-C concentration and HDL remodeling in CETP genc polymorphism

Study on plasma HDL-C concentration and HDL remodeling in CETP genc polymorphism
CETP基因多态性血浆HDL-C浓度及HDL重构研究
批准号:
12671129
负责人:
MURAKAMI Toru
金额:
$0.7万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

MURAKAMI Toru的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CETP Taq I B B1B1 polymorphism was an important genotype affecting to plasma HDL cholesterol concentration in multiple clinical factors matched subjects. It was shown that the level of plasma HDL-C of the subjects with B1B1 polymorphism was lower about 8% compared with those of B2B2.In diabetic patients, the level of plasma HDL-C of the subjects with B2B2 was higher about 20% compared with those of B1B1.However it was indicated that this result had not always good effects to prevent atherosclerosis. Because in diabetic patients, the ability of cholesterol transport from donor lipoprotein to acceptor lipoproteins is basically decreased. Therefore increased plasma HDL-C level by the inhibitory effect of reverse cholesterol transport will not be contributed to the prevention of atherosclerosis. Our study furthermore indicated that this condition was more enhanced in patients with hypertriglyceridemics and obesity. We concluded that Taq IB B2B2 genotype itself may contribute to the increment of plasma HDL-C concentration but the role of this gene polymorphism concerning the preventive effects for atherosclerosis in diabetics, obese subjects and hypertriglyceridemics was controversial. Recently we found that the effect of HDL-C increment after statin was the strongest in primary hypercholesterolemics with CETP Taq IB B1B1 polymorphism.
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
村上 透, 山田信博: "メデイクイックブック(分担執筆)患者さんによくわかる検査手術の説明と生活指導 第二版"金原出版. 10 (2001)
村上彻、山田信宏:《Mediquick Book(合着)患者容易理解的检查和手术说明以及生活方式指导第 2 版》金原出版社 10(2001 年)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamazaki Y.,Osaka T.,Murakami T.,Inoue S.: "JTT-501, a New Oral Hypotriglycemic Agent, Hypertriglyceridemia in Zucker Fatty and Ventromedial Hypothalamus-Lesioned Obese Rats."Metabolism. 49(5). 574-578 (2000)
Yamazaki Y.、Osaka T.、Murakami T.、Inoue S.:“JTT-501,一种新型口服降血糖药,Zucker 脂肪和腹内侧下丘脑损伤肥胖大鼠的高甘油三酯血症。”代谢。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamazaki Y., Osaka T., Murakami T., Inoue S.: "JTT-501, a New Oral Hypotriglycemic Agent, Reverses Hypertriglyceridemia in Zucker Fatty and Ventromedial Hypothalamus-I esioned Obese Rats"Metab lism. 49(5). 574-578 (2000)
Yamazaki Y.、Osaka T.、Murakami T.、Inoue S.:“JTT-501,一种新型口服降血糖药,可逆转 Zucker 脂肪和下丘脑腹内侧区肥胖大鼠的高甘油三酯血症”代谢。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Miida, T.Ozaki, K.Murakami, T.Kashiwa, t.Yamadera, Tsuda, T.Inano, K.Okada, N: "Pre Bhigh-density lipoprotein(pre β1-HDL) concermation can change with low-dersity lipoporotein cholcslerol(LDL-C)concentration independent of cholesteryl ester transfect prot
Miida、T.Ozaki、K.Murakami、T.Kashiwa、t.Yamadera、Tsuda、T.Inano、K.Okada、N:“前 B 高密度脂蛋白(前 β1-HDL)浓度可随低密度脂蛋白改变胆固醇 (LDL-C) 浓度与胆固醇酯转染蛋白无关
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
21
    Study on HDL metabolism and atherogenesity in type 2 diabetics with Taq IBB2B2 polymorphism
    国内基金
    海外基金
    番茄红素通过LXRα-CETP-ABCA1/G1信号通路抑制支架内新生动脉粥样硬化形成的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      15.0万元
    • 批准年份:
      2024
    • 负责人:
      侯经远
    • 依托单位:
    护心通络方通过干预CETP介导脂质代谢防治动脉粥样硬化的作用机制
    新型双位点CETP抑制剂的设计、合成及生物活性研究
    • 批准号:
      81703367
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.1万元
    • 批准年份:
      2017
    • 负责人:
      袁浩亮
    • 依托单位:
    五环三萜类CETP抑制剂的设计、合成及活性评价
    • 批准号:
      81602957
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      17.3万元
    • 批准年份:
      2016
    • 负责人:
      陈冬寅
    • 依托单位: